Nantahala Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nantahala Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-400,000	Closed	-$44.8M	–	138
2021 Q4	$44.8M	Buy	+400,000	New	+$48.2M	1.58%	19
2015 Q3	–	Sell	-90,000	Closed	-$7.57M	–	72
2015 Q2	$7.57M	Sell	90,000 -60,000	-40%	-$4.67M	1.11%	31
2015 Q1	$11.3M	Buy	+150,000	New	+$10.5M	1.88%	12

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nantahala Capital Management's XBI Position: Q4 2024 in Review

Nantahala Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 21,646 shares — an estimated $2.1M sold.

Nantahala Capital Management first reported a position in XBI in Q1 2024 and held it in 3 quarters. The position peaked at $3.99M in Q1 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

Nantahala Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
Nantahala Capital Management sold 21,646 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $2.1M.
Nantahala Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 3 quarters.
Nantahala Capital Management's State Street SPDR S&P Biotech ETF position peaked at $3.99M in Q1 2024.
738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.